What Is NTA Verification and Why Does It Matter When Sourcing Exosomes?
Every exosome supplier uses the phrase "NTA-verified." It appears in marketing copy, on product pages, and in sales conversations. But when practitioners ask what it actually means — what the instrument measures, what the numbers represent, and what a good result looks like — the answers are almost never provided.
This article explains exactly what Nanoparticle Tracking Analysis is, what the size distribution graph is telling you, and why the difference between an NTA-verified result and a marketing claim matters when you are deciding which biologic supplier to trust with your practice.
What Is Nanoparticle Tracking Analysis?
Nanoparticle Tracking Analysis (NTA) is an instrument-based method for measuring the size distribution and concentration of particles in liquid suspension. It works by tracking individual particles as they move under Brownian motion — the random thermal movement of particles suspended in liquid.
A laser beam illuminates the sample. A high-sensitivity camera captures the light scattered by individual particles as they move through the beam. Software then tracks each particle's movement frame by frame. Because Brownian motion speed is directly related to particle size — smaller particles move faster, larger particles move slower — the instrument can calculate the actual diameter of each individual particle it observes. This is the Stokes-Einstein equation applied at the nanoscale.
The result is a particle-by-particle size distribution graph — not an average, not an estimate, not a batch approximation. Every particle tracked individually, counted, and sized.
Reading the NTA Graph — What Each Zone Means
An NTA output is a histogram: particle concentration on the Y axis, particle diameter in nanometers on the X axis. The graph shows you not just how many particles are in a sample — but what sizes those particles are. Size matters because different size ranges represent fundamentally different types of particles with different biological origins.
Here is what each zone of the size distribution represents, based on published extracellular vesicle literature:
NTA size distribution graph with zone annotations — Zoomed in and Explained.
NTA size distribution graph with zone annotations — Stem Nova Network lot 3D-A1-2410-D. Mean particle size: 134.0 nm. Concentration: 6.0×10¹⁰ P/mL.
⚠ < 30 nm — Sub-EV Zone
What it is: Protein complexes, free proteins, membrane fragments, and cellular debris. Not intact exosomes. Intact extracellular vesicles physically cannot be smaller than approximately 30nm — their lipid bilayer structure sets a minimum size floor. Particles appearing below 30nm in an NTA graph indicate contamination, poor purification, or processing byproducts. A high concentration of sub-30nm particles is a product quality signal — not evidence of small, potent exosomes.
✓ 30 – 150 nm — Exosome Zone
What it is: True extracellular vesicles — exosomes released via the endolysosomal pathway from multivesicular bodies (MVBs). This is the biologically active zone. Published literature places the exosome size range at 30–150nm, with the peak therapeutic concentration typically between 50–130nm. A well-manufactured exosome product should show the majority of its particle concentration here, ideally with a tight, symmetrical peak. Our lot mean of 134.0nm falls squarely in this zone.
150 – 500 nm — Microvesicle Zone
What it is: Microvesicles — larger extracellular vesicles formed by direct outward budding from the plasma membrane. Microvesicles are a different class of EV than exosomes with a different biogenesis pathway. Some microvesicles carry signaling cargo, but they are less information-dense than exosomes and represent a different biological entity. A supplier's NTA graph showing a large shoulder in this zone signals that what they are counting as "exosomes" includes a significant microvesicle population.
⚠ 500 nm – 1000 nm+ — Large EV Zone
What it is: Apoptotic bodies and large cellular debris — byproducts of cell death and membrane fragmentation. Particles in this zone are not exosomes. Their presence in significant concentration indicates either manufacturing quality concerns or inadequate purification. A well-manufactured exosome product should show minimal signal here. Large-particle shoulders on an NTA graph are a red flag worth asking your supplier to explain.
A Common Misconception — Clarified
A misconception that circulates in the practitioner community is that particles above 200nm on an NTA graph represent proteins. This is not accurate. Protein aggregates and free proteins can appear across a range of sizes — often below 60nm — and overlap with the exosome size range, which is one reason proper purification matters. The large end of the NTA spectrum (above 200nm) represents microvesicles and apoptotic bodies — larger membrane-bound vesicles with different biogenesis than exosomes, not protein content.
Similarly, particles appearing below 30nm are not "damaged exosomes" — they are particles that are structurally too small to be intact membrane-bound vesicles. They are sub-EV debris: protein fragments, free membrane lipids, and processing byproducts. Their presence indicates what is in the preparation alongside the exosomes — not the state of the exosomes themselves.
What a Good NTA Result Looks Like
When reviewing an NTA report from a supplier, four things matter:
Peak location — does it fall in the exosome zone?
The distribution peak should fall between 50–150nm. A mean particle size outside this range — particularly above 200nm — means the bulk of what is being counted is not in the classical exosome size range. Stem Nova Network lot 3D-A1-2410-D: mean 134.0nm. ✓
Peak shape — is the distribution tight or diffuse?
A narrow, symmetrical peak indicates a homogenous, well-purified EV population. A broad, flat, or multi-peaked distribution indicates a heterogeneous sample — multiple particle types present together. Tight peaks mean lot-to-lot consistency is achievable. Diffuse distributions mean it is not.
Concentration — is the count verified on the final product?
The particle concentration reported on the NTA must reflect the final shipped product — not a pre-purification measurement, not a pre-lyophilization measurement, and not an extrapolated figure. Ask specifically: "Is this NTA result from the final vial formulation?" Stem Nova Network concentration: 6.0×10¹⁰ P/mL — measured on the final product. ✓
Large-particle shoulder — is the >500nm zone clean?
Minimal signal above 500nm indicates low apoptotic body and large debris contamination. A prominent shoulder or elevated baseline in the large-particle zone signals purification quality concerns. Review the full distribution graph — not just the peak and total count number.
How NTA Differs from a Marketing Count Claim
| What Suppliers Say | What It Actually Means Without NTA Documentation | What NTA Verification Confirms |
|---|---|---|
| "60 billion exosomes per vial" | Unverified count claim. No instrument data. Could include debris, microvesicles, protein aggregates. | Particle-by-particle count of 6.0×10¹⁰ P/mL confirmed by ZetaView instrument. Size distribution confirms particles are in exosome range. |
| "High potency formulation" | No instrument basis. Marketing language. Cannot be verified. | NTA shows peak at 134nm, tight distribution, minimal large-particle shoulder. Concentration documented per lot. |
| "NTA-tested" | Test may have been run on source material, not final product. Results may not be lot-specific. | Lot-specific NTA on the final formulation shipped to you, referenced by lot number on the CoA. |
| "Quality tested product" | Vague. No specification of what was tested, how, or what the acceptance criteria were. | Particle concentration, mean size, size distribution, sterility, mycoplasma, endotoxin — all documented with specifications and results on lot-specific CoA. |
Reading Our Actual Lot Data
Every Stem Nova Network exosome biologic order ships with a lot-specific Certificate of Analysis that includes the full NTA output. Here is what our data shows for lot 3D-A1-2410-D:
- Particle Concentration: 6.0×10¹⁰ particles/mL — measured by ZetaView NTA instrument using scatter mode
- Mean Particle Size: 134.0 nm — falls within the classical exosome size range of 30–150nm
- Size Distribution: Tight, symmetrical peak centered at 134nm with minimal microvesicle shoulder and clean large-particle baseline
- Total Protein (Bradford Assay): 4,824.6 μg/mL — protein content of the secretome matrix co-isolated with the EVs
- EV Origin: Human umbilical cord tissue MSC (hUCT-MSC), first-pregnancy donor
The 134nm mean places our primary particle population in the upper end of the exosome range — consistent with the 3D bioreactor culture system we use, which is documented in published literature to produce up to 19.4x higher EV yield per cell than standard 2D flat culture. Higher-yield 3D culture systems tend to produce slightly larger EVs on average than lower-yield 2D systems, reflecting the richer secretome environment of the bioreactor.
What to Ask Any Exosome Supplier
Before purchasing any exosome biologic, request the following and evaluate the answers:
- "Can I see the NTA report for the specific lot I am receiving?" — Not a sample report, not a product-line CoA. The lot-specific NTA output for the vials in your order.
- "Was the NTA run on the final formulation or on source material?" — The count must reflect what is in the vial as shipped.
- "What is the mean particle size and size distribution?" — Review the full histogram, not just the total count number.
- "What instrument was used and what are the acquisition settings?" — Different camera gain and laser power settings can artificially inflate or deflate particle counts.
- "Is there a large-particle shoulder above 300nm in the distribution?" — A significant shoulder is a purification quality signal worth asking about.
Request Documentation Before You Buy
Lot-specific CoAs, NTA reports, and full supplier documentation available to licensed professionals upon credential verification. Most practices approved within 24 hours.
Enroll Your Practice Today → Contact Our TeamFrequently Asked Questions
Why does NTA matter more than a simple particle count claim?
A particle count claim without NTA documentation has no instrument verification behind it. NTA tells you not just how many particles are in a vial, but what those particles are — their size distribution reveals whether the bulk of the count falls in the exosome zone (50–150nm), the microvesicle zone (150–500nm), or the debris zone (<30nm or >500nm). The number alone tells you nothing about the composition of what you are sourcing.
Is a higher particle count always better?
Not necessarily. A higher count with a diffuse size distribution, a prominent microvesicle shoulder, or a significant sub-30nm debris peak means a large portion of that count is not in the classical exosome range. What matters is count + size distribution together — how many particles, and where they fall on the distribution graph.
What is the difference between NTA and DLS (Dynamic Light Scattering)?
Dynamic Light Scattering (DLS) measures an average particle size across the entire sample simultaneously — it does not track individual particles. NTA tracks each particle individually under Brownian motion. For heterogeneous samples like exosome preparations — which contain particles of many different sizes — NTA provides a true size distribution profile. DLS gives a single weighted average that can be misleading when particle populations are mixed. NTA is the accepted gold standard for exosome characterization.
What does "lot-specific CoA" mean and why does it matter?
A lot-specific Certificate of Analysis documents test results for a specific production batch — the exact vials you received. Some suppliers provide a product-line CoA — a generic document showing representative specifications that does not reflect the specific lot you purchased. Lot-specific documentation means the NTA was run on your batch, sterility was confirmed on your batch, and the results on the document correspond to the vials in your order. This is the appropriate documentation standard for biologic sourcing.
Related Resources
- Lyophilized vs. Liquid Exosomes: What Clinics Need to Know Before Buying
- Are Exosomes FDA Approved? What Practitioners Need to Understand
- 3D Exosomes vs PRP: Manufacturing & Sourcing Comparison
- Quality & Testing Standards: NTA Reports, CoAs, and cGMP Compliance
- Browse the Stem Nova Biologics Catalog